The ongoing pursuit of a prophylactic HSV vaccine

Reviews in Medical Virology

Volumn 22, Issue 5, 2012, Pages 285-300

  Chung, Erin ^a   Sen, Jonathan ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b The Australian National University   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; DNA VACCINE; GENEVAX; HERPES SIMPLEX VACCINE; HERPV; IMMUNOVEX; INACTIVATED VACCINE; SUBUNIT VACCINE; THERAHERP; UNCLASSIFIED DRUG; VIRUS VECTOR; VITAHERPAVAC;

ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; BLINDNESS; CELLULAR IMMUNITY; DRUG EFFICACY; DRUG SAFETY; HERPES SIMPLEX; HERPES SIMPLEX VIRUS; HUMAN; IMMUNE SYSTEM; INFECTION PREVENTION; MORBIDITY; MORTALITY; NONHUMAN; REVIEW; VIRUS SHEDDING;

CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; HERPES SIMPLEX; HERPES SIMPLEX VIRUS VACCINES; HUMANS;

EID: 84865776618     PISSN: 10529276     EISSN: 10991654     Source Type: Journal    
DOI: 10.1002/rmv.1709     Document Type: Review

References (141)

1. Wald A, Corey L. Persistence in the population: epidemiology, transmission. In Human Herpes Viruses: Biology, Therapy, and Immunoprophylaxis, Arvin A, Campadelli-Fiume G, Mocarski E, et al. (eds). Cambridge University Press: Cambridge, 2007.
2. Yamada S, Kameyama T, Nagaya S, Hashizume Y, Yoshida M. Relapsing herpes simplex encephalitis: pathological confirmation of viral reactivation. Journal of Neurology, Neurosurgery, and Psychiatry 2003; 74: 262-264.
3. Wald A, Link K. Risk of human immunodeficiency virus infection in herpes simplex virus type 2-seropositive persons: a meta-analysis. Journal of Infectious Diseases 2002; 185: 45-52.
4. Freeman EE, Weiss HA, Glynn JR, et al. Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS 2006; 20: 73-83.
5. Mbopi-Kéou FX, Legoff J, Grésenguet G, et al. Genital shedding of herpes simplex virus-2 DNA and HIV-1 RNA and proviral DNA in HIV-1- and herpes simplex virus-2-coinfected African women. Journal of Acquired Immune Deficiency Syndromes 2003; 33: 121-124.
6. Mbopi-Keou FX, Robinson NJ, Mayaud P, Belec L, Brown DWG. Herpes simplex virus type 2 and heterosexual spread of human immunodeficiency virus infection in developing countries: hypotheses and research priorities. Clinical Microbiology and Infection 2003; 9: 161-171.
7. Corey L, Wald A, Patel R, et al. Once-daily valacyclovir to reduce the risk of transmission of genital herpes. The New England Journal of Medicine 2004; 350: 11-20. DOI: 10.1056/NEJMoa035144
8. Smith PD, Roberts CM. American College Health Association annual Pap test and sexually transmitted infection survey: 2006. Journal of American College Health 2009; 57: 389-394.
9. Ryder N, Jin F, McNulty AM, Grulich AE, Donovan B. Increasing role of herpes simplex virus type 1 in first-episode anogenital herpes in heterosexual women and younger men who have sex with men, 1992-2006. Sexually Transmitted Infections 2009; 85: 416-419. DOI: 10.1136/sti.2008.033902
10. Smith JS, Robinson NJ. Age-specific prevalence of infection with herpes simplex virus types 2 and 1: a global review. Journal of Infectious Diseases 2002; 186: S3-S28.
11. Howard M, Sellors JW, Jang D, et al. Regional distribution of antibodies to herpes simplex virus type 1 (HSV-1) and HSV-2 in men and women in Ontario, Canada. Journal of Clinical Microbiology 2003; 41: 84-89.
12. Cunningham AL, Taylor R, Taylor J, Marks C, Shaw J, Mindel A. Prevalence of infection with herpes simplex virus types 1 and 2 in Australia: a nationwide population based survey. Sexually Transmitted Infections 2006; 82: 164-168.
13. Chen CY, Ballard RC, Beck-Sague CM, et al. Human immunodeficiency virus infection and genital ulcer disease in South Africa: the herpetic connection. Sexually Transmitted Diseases 2000; 27: 21-29.
14. Xu F, Schillinger JA, Sternberg MR, et al. Seroprevalence and coinfection with herpes simplex virus type 1 and type 2 in the United States, 1988-1994. Journal of Infectious Diseases 2002; 185: 1019-1024.
15. Looker KJ, Garnett GP, Schmid GP. An estimate of the global prevalence and incidence of herpes simplex virus type 2 infection. Bulletin of the World Health Organization 2008; 86: 805-812.
16. Kimberlin DW. Neonatal herpes simplex infection. Clinical Microbiology Reviews 2004; 17: 1-13.
17. Thompson C, Whitley R. Neonatal herpes simplex virus infections: where are we now? In Hot Topics in Infection and Immunity in Children VII, Volume 697, Curtis N, Finn A, Pollard AJ (eds). Advances in Experimental Medicine and Biology. Springer: New York, 2011; 221-230.
18. Kimberlin DW, Lin CY, Jacobs RF, et al. Safety and efficacy of high-dose intravenous acyclovir in the management of neonatal herpes simplex virus infections. Pediatrics 2001; 108: 230-238.
19. Jones CA, Walker KS, Badawi N. Antiviral agents for treatment of herpes simplex virus infection in neonates. Cochrane Database of Systematic Reviews 2009; CD004206. DOI: 10.1002/14651858.CD004206.pub2
20. Patel R, Paya CY. Infections in solid-organ transplant recipients. Clinical Microbiology Reviews 1997; 10: 86.
21. Schacker T, Ryncarz AJ, Goddard J, Diem K, Shaughnessy M, Corey L. Frequent recovery of HIV-1 from genital herpes simplex virus lesions in HIV-1-infected men. JAMA 1998; 280: 61-66. DOI: 10.1001/jama.280.1.61
22. Mole L, Ripich S, Margolis D, Holodniy M. The impact of active herpes simplex virus infection on human immunodeficiency virus load. Journal of Infectious Diseases 1997; 176: 766-770. DOI: 10.1086/517297
23. Huang E, Perkins EM, Desai P. Structural features of the scaffold interaction domain at the N terminus of the major capsid protein (VP5) of herpes simplex virus type 1. Journal of Virology 2007; 81: 9396-9407.
24. Rupp R, Bernstein DI. The potential impact of a prophylactic herpes simplex vaccine. Expert Opinion on Emerging Drugs 2008; 13: 41-52. DOI: 10.1517/14728214.13.1.41
25. Wittels M, Spear PG. Penetration of cells by herpes simplex virus does not require a low pH-dependent endocytic pathway. Virus Research 1991; 18: 271-290.
26. Reske A, Pollara G, Krummenacher C, Chain BM, Katz DR. Understanding HSV-1 entry glycoproteins. Reviews in Medical Virology 2007; 17: 205-215. DOI: 10.1002/rmv.531
27. Spear PG. Herpes simplex virus: receptors and ligands for cell entry. Cellular Microbiology 2004; 6: 401-410.
28. Montgomery RI, Warner MS, Lum BJ, Spear PG. Herpes simplex virus-1 entry into cells mediated by a novel member of the TNF/NGF receptor family. Cell 1996; 87: 427-436.
29. Campadelli-Fiume G, Amasio M, Avitabile E, et al. The multipartite system that mediates entry of herpes simplex virus into the cell. Reviews in Medical Virology 2007; 17: 313-326.
30. Atanasiu D, Whitbeck JC, de Leon MP, et al. Bimolecular complementation defines functional regions of herpes simplex virus gB that are involved with gH/gL as a necessary step leading to cell fusion. Journal of Virology 2010; 84: 3825-3834. DOI: 10.1128/jvi.02687-09
31. Perng GC, Jones C. Towards an understanding of the herpes simplex virus type 1 latency-reactivation cycle. Interdisciplinary Perspective in Infectious Diseases 2010; 2010: 1-18.
32. Honess RW, Roizman B. Regulation of herpes virus macromolecular synthesis. I: cascade regulation of the synthesis of three groups of viral proteins. Journal of Virology 1974; 14: 8-19.
33. McGeoch DJ, Rixon FJ, Davison AJ. Topics in herpes virus genomics and evolution. Virus Research 2006; 117: 90-104. DOI: 10.1016/j.virusres.2006.01.002
34. Frampton AR Jr, Goins WF, Nakano K, Burton EA, Glorioso JC. HSV trafficking and development of gene therapy vectors with applications in the nervous system. Gene Therapy 2005; 12: 891-901.
35. Maggioncalda J, Mehta A, Su YH, Fraser NW, Block TM. Correlation between herpes simplex virus type 1 rate of reactivation from latent infection and the number of infected neurons in trigeminal ganglia. Virology 1996; 225: 72-81.
36. Everett RD. ICP0, a regulator of herpes simplex virus during lytic and latent infection. Bioessays 2000; 22: 761-770.
37. Alsallaq RA, Schiffer JT, Longini IMJ, Wald A, Corey L, Abu-Raddad LJ. Population level impact of an imperfect prophylactic vaccine for herpes simplex virus-2. Sexually Transmitted Diseases 2010; 37: 290-297.
38. Ferenczy MW. Prophylactic vaccine strategies and the potential of therapeutic vaccines against herpes simplex virus. Current Pharmaceutical Design 2007; 13: 1975-1988.
39. Khanna KM, Lepisto AJ, Decman V, Hendricks RL. Immune control of herpes simplex virus during latency. Current Opinion in Immunology 2004; 16: 463-469.
40. Schiffer JT, Abu-Raddad L, Mark KE, et al. Mucosal host immune response predicts the severity and duration of herpes simplex virus-2 genital tract shedding episodes. Proceedings of the National Academy of Sciences of the United States of America 2010; 107: 18973-18978.
41. Lee AJ, Ashkar AA. Herpes simplex virus-2 in the genital mucosa: insights into the mucosal host response and vaccine development. Current Opinion in Infectious Diseases 2012; 25: 92-99.
42. Chan T, Barra NG, Lee AJ, Ashkar AA. Innate and adaptive immunity against herpes simplex virus type 2 in the genital mucosa. Journal of Reproductive Immunology 2011; 88: 210-218.
43. Koelle DM, Chen HB, Gavin MA, Wald A, Kwok WW, Corey L. CD8 CTL from genital herpes simplex lesions: recognition of viral tegument and immediate early proteins and lysis of infected cutaneous cells. Journal of Immunology 2001; 166: 4049-4058.
44. Lucas M, Schachterle W, Oberle K, Aichele P, Diefenbach A. Dendritic cells prime natural killer cells by trans-presenting interleukin 15. Immunity 2007; 26: 503-517.
45. Decman V, Freeman ML, Kinchington PR, Hendricks RL. Immune control of HSV-1 latency. Viral Immunology 2005; 18: 466-473.
46. Corey L, Langenberg AG, Ashley R, et al. Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. JAMA 1999; 282: 331-340. DOI: 10.1001/jama.282.4.331
47. Simmons A, Tscharke DC. Anti-CD8 impairs clearance of herpes simplex virus from the nervous system: implications for the fate of virally infected neurons. The Journal of Experimental Medicine 1992; 175: 1337-1344.
48. St. Leger AJ, Peters B, Sidney J, Sette A, Hendricks RL. Defining the herpes simplex virus-specific CD8+ T cell repertoire in C57BL/6 mice. The Journal of Immunology 2011; 186: 3927-3933. DOI: 10.4049/jimmunol.1003735
49. Akhrameyeva NV, Zhang P, Sugiyama N, Behar SM, Yao F. Development of a glycoprotein D-expressing dominant-negative and replication-defective herpes simplex virus 2 (HSV-2) recombinant viral vaccine against HSV-2 infection in mice. Journal of Virology 2011; 85: 5036-5047. DOI: 10.1128/jvi.02548-10
50. + T cell function and epitope breadth among persons with genital herpes. Journal of Clinical Immunology 2010; 30: 703-722.
51. Nakanishi Y, Lu B, Gerard C, Iwasaki A. CD8 + T lymphocyte mobilization to virus-infected tissue requires CD4+ T-cell help. Nature 2009; 462: 510-513.
52. Milligan GN, Bernstein DI, Bourne N. T lymphocytes are required for protection of the vaginal mucosae and sensory ganglia of immune mice against reinfection with herpes simplex virus type 2. Journal of Immunology 1998; 160: 6093-6100.
53. Mertz GJ, Ashley R, Burke RL, et al. Double-blind, placebo-controlled trial of a herpes simplex virus type 2 glycoprotein vaccine in persons at high risk for genital herpes infection. Journal of Infectious Diseases 1990; 161(4): 653-660.
54. Friedman HM. Immune evasion by herpes simplex virus type 1, strategies for virus survival. Transactions of the American Clinical and Climatological Association 2003; 114: 103-112.
55. Stanberry LR. Evaluation of herpes simplex virus vaccines in animals: the guinea pig vaginal model. Reviews of Infectious Diseases 1991; 13: S920-S923.
56. Sedarati F, Javier RT, Stevens JG. Pathogenesis of a lethal mixed infection in mice with two non-neuroinvasive herpes simplex virus strains. Journal of Virology 1988; 62: 3037-3039.
57. Roizman B, Warren J, Thuning C.A., Fanshaw MS, Norrild B, Meignier B. Application of molecular genetics to the design of live herpes simplex virus vaccines. Developments in Biological Standardization 1982; 52: 287-304.
58. Whitley RJ. Herpes Simplex Vaccines, 2nd edn. Marcel Dekker: New York, 1997; 727-748.
59. Prichard MN, Kaiwar R, Jackman WT, et al. Evaluation of AD472, a live attenuated recombinant herpes simplex virus type 2 vaccine in guinea pigs. Vaccine 2005; 23: 5424-5431.
60. Spector FC, Kern ER, Palmer J, et al. Evaluation of a live attenuated recombinant virus RAV 9395 as a herpes simplex virus type 2 vaccine in guinea pigs. The Journal of Infectious Diseases 1998; 177: 1143-1154.
61. Gyotoku T, Ono F, Aurelian L. Development of HSV-specific CD4+ Th1 responses and CD8+ cytotoxic T lymphocytes with antiviral activity by vaccination with the HSV-2 mutant ICP10[Delta]PK. Vaccine 2002; 20: 2796-2807.
62. Kembel M. Biovex initiates phase 1 clinical trial with its genital herpes vaccine, IMMUNOVEXHSV2. BioVex: Woburn, MA, 2010.
63. Thomas SK, Thornton M, Bullock P, et al. Delivery of HPV antigens using a modified HSV-2 vector: development of a combined vaccine for HPV and HSV-2. Central European Journal of Public Health 2008; 16(Supp. 76): 34.
64. Da Costa XJ, Bourne N, Knipe DM. Construction and characterization of a replication-defective herpes simplex virus 2 ICP8 mutant strain and its use in immunization studies in a guinea pig model of genital disease. Virology 1997; 232: 1-12.
65. Keadle TL, Laycock KA, Morris JL, et al. Therapeutic vaccination with vhs-herpes simplex virus reduces the severity of recurrent herpetic stromal keratitis in mice. Journal of General Virology 2002; 83: 2361-2365.
66. McLean CS, Erturk M, Jennings R, et al. Protective vaccination against primary and recurrent disease caused by herpes simplex virus (HSV) type 2 using a genetically disabled HSV-1. The Journal of Infectious Diseases 1994; 170: 1100-1109.
67. Aurelian L. Herpes simplex virus type 2 vaccines: new ground for optimism? Clinical and Diagnostic Laboratory Immunology 2004; 11: 437-445. DOI: 10.1128/cdli.11.3.437-445.2004
68. Hoshino Y, Pesnicak L, Dowdell KC, et al. Protection from herpes simplex virus (HSV)-2 infection with replication-defective HSV-2 or glycoprotein D2 vaccines in HSV-1-seropositive and HSV-1-seronegative guinea pigs. Journal of Infectious Diseases 2009; 200: 1088-1095. DOI: 10.1086/605645
69. Reszka NJ, Dudek T, Knipe DM. Construction and properties of a herpes simplex virus 2dl5-29 vaccine candidate strain encoding an HSV-1 virion host shutoff protein. Vaccine 2010; 28: 2754-2762.
70. Brans R, Yao F. Immunization with a dominant-negative recombinant herpes simplex virus (HSV) type 1 protects against HSV-2 genital disease in guinea pigs. BMC Microbiology 2010; 10: 163.
71. Brittle EE, Wang F, Lubinski JM, Bunte RM, Friedman HM. A replication-competent, neuronal spread-defective, live attenuated herpes simplex virus type 1 vaccine. Journal of Virology 2008; 82: 8431-8441.
72. McClements WL, Armstrong ME, Keys RD, Liu MA. Immunization with DNA vaccines encoding glycoprotein D or glycoprotein B, alone or in combination, induces protective immunity in animal models of herpes simplex virus-2 disease. Proceedings of the National Academy of Sciences of the United States of America 1996; 93: 11414-11420.
73. Bourne N, Milligan GN, Schleiss MR, Bernstein DI, Stanberry LR. DNA immunization confers protective immunity on mice challenged intravaginally with herpes simplex virus type 2. Vaccine 1996; 14: 1230-1234.
74. Manickan E, Yu Z, Rouse RJ, Wire WS, Rouse BT. Induction of protective immunity against herpes simplex virus with DNA encoding the immediate early protein ICP 27. Viral Immunology 1995; 8: 53-61.
75. Hoshino Y, Dalai SK, Wang K, et al. Comparative efficacy and immunogenicity of replication-defective, recombinant glycoprotein, and DNA vaccines for herpes simplex virus 2 infections in mice and guinea pigs. Journal of Virology 2005; 79: 410-418. DOI: 10.1128/jvi.79.1.410-418.2005
76. Manickan E, Rouse R, Yu Z, Wire W, Rouse B. Genetic immunization against herpes simplex virus. Protection is mediated by CD4+ T lymphocytes. Journal of Immunology 1995; 155: 259-265.
77. Sin J-I, Kim JJ, Arnold RL, et al. IL-12 gene as a DNA vaccine adjuvant in a herpes mouse model: IL-12 enhances Th1-type CD4+ T cell-mediated protective immunity against herpes simplex virus-2 challenge. Journal of Immunology 1999; 162: 2912-2921.
78. Harle P, Noisakran S, Carr DJJ. The application of a plasmid DNA encoding IFN-α1 postinfection enhances cumulative survival of herpes simplex virus type 2 vaginally infected mice. Journal of Immunology 2001; 166: 1803-1812.
79. Sin J-I, Kim JJ, Pachuk C, Satishchandran C, Weiner DB. DNA vaccines encoding interleukin-8 and RANTES enhance antigen-specific Th1-type CD4+ T-cell-mediated protective immunity against herpes simplex virus type 2 in vivo. Journal of Virology 2000; 74: 11173-11180. DOI: 10.1128/jvi.74.23.11173-11180.2000
80. Kim TW, Hung C-F, Ling M, et al. Enhancing DNA vaccine potency by coadministration of DNA encoding antiapoptotic proteins. The Journal of Clinical Investigation 2003; 112: 109-117.
81. Gallichan WS, Woolstencroft RN, Guarasci T, McCluskie MJ, Davis HL, Rosenthal KL. Intranasal immunization with CpG oligodeoxynucleotides as an adjuvant dramatically increases IgA and protection against herpes simplex virus-2 in the genital tract. Journal of Immunology 2001; 166: 3451-3457.
82. Meseda CA, Elkins KL, Merchlinsky MJ, Weir JP. Prime-boost immunization with DNA and modified vaccinia virus Ankara vectors expressing herpes simplex virus-glycoprotein D elicits greater specific antibody and cytokine responses than DNA vaccine alone. The Journal of Infectious Diseases 2002; 186: 1065-1073. DOI: 10.1086/344234
83. Cattamanchi A, Posavad CM, Wald A, et al. Phase I study of a herpes simplex virus type 2 (HSV-2) DNA vaccine administered to healthy, HSV-2-seronegative adults by a needle-free injection system. Clinical and Vaccine Immunology 2008; 15: 1638-1643. DOI: 10.1128/cvi.00167-08
84. Kenney R, Sullivan S, Shlapobersky M, et al. Development of an adjuvanted plasmid DNA HSV-2 vaccine for prophylactic and therapeutic applications (scientific poster). In International Herpes Workshop, Salt Lake City, Vical, 2010.
85. Pouyanfard S, Bamdad T, Parsania M, Hashemi H, Mohammadi MG. Impact of timing strategy of LIGHT, a new TNF superfamily on immune platform induced by HSV-1 gB DNA vaccine. Cytokine 2010; 50: 99-103.
86. Gallichan WS, Johnson DC, Graham FL, Rosenthal KL. Mucosal immunity and protection after intranasal immunization with recombinant adenovirus expressing herpes simplex virus glycoprotein B. Journal of Infectious Diseases 1993; 168: 622-629.
87. Chabalgoity JA, Khan CMA, Nash AA, Hormaeche CE. A Salmonella typhimurium htrA live vaccine expressing multiple copies of a peptide comprising amino acids 8-23 of herpes simplex virus glycoprotein D as a genetic fusion to tetanus toxin fragment C protects mice from herpes simplex virus infection. Molecular Microbiology 1996; 19: 791-801.
88. Bernstein DI. Effect of route of vaccination with vaccinia virus expressing HSV-2 glycoprotein D on protection from genital HSV-2 infection. Vaccine 2000; 18: 1351-1358.
89. Orr MT, Orgun NN, Wilson CB, Way SS. Cutting edge: recombinant Listeria monocytogenes expressing a single immune-dominant peptide confers protective immunity to herpes simplex virus-1 infection. Journal of Immunology 2007; 178: 4731-4735.
90. Gallichan SW, Rosenthal KL. Specific secretory immune responses in the female genital tract following intranasal immunization with a recombinant adenovirus expressing glycoprotein B of herpes simplex virus. Vaccine 1995; 13: 1589-1595.
91. Heineman T, Connelly B, Bourne N, Stanberry L, Cohen J. Immunization with recombinant varicella-zoster virus expressing herpes simplex virus type 2 glycoprotein D reduces the severity of genital herpes in guinea pigs. Journal of Virology 1995; 69: 8109-8113.
92. Karem K, Bowen J, Kuklin N, Rouse B. Protective immunity against herpes simplex virus (HSV) type 1 following oral administration of recombinant Salmonella typhimurium vaccine strains expressing HSV antigens. Journal of General Virology 1997; 78: 427-434.
93. Yuen TJ, Flesch IEA, Hollett NA, et al. Analysis of A47, an immunoprevalent protein of vaccinia virus, leads to a reevaluation of the total antiviral CD8+ T cell response. Journal of Virology 2010; 84: 10220-10229. DOI: 10.1128/jvi.01281-10
94. Rooney JF, Wohlenberg CR, Moss B, Notkins AL. Live vaccinia virus recombinants expressing herpes simplex virus genes [with discussion]. Reviews of Infectious Diseases 1991; 13: S898-S903.
95. AlphaVax Progresses a Prophylactic HSV Vaccine in News Release, volume 59. Alphavax: North Carolina, 2009.
96. Rayner JO, Dryga SA, Kamrud KI. Alphavirus vectors and vaccination. Reviews in Medical Virology 2002; 12: 279-296.
97. Kowalski J, Adkins K, Gangolli S, et al. Evaluation of neurovirulence and biodistribution of Venezuelan equine encephalitis replicon particles expressing herpes simplex virus type 2 glycoprotein D. Vaccine 2007; 25: 2296-2305.
98. Hariharan MJ, Driver DA, Townsend K, et al. DNA immunization against herpes simplex virus: enhanced efficacy using a Sindbis virus-based vector. Journal of Virology 1998; 72: 950-958.
99. Bernstein DI, Reap EA, Katen K, et al. Randomized, double-blind, phase 1 trial of an alphavirus replicon vaccine for cytomegalovirus in CMV seronegative adult volunteers. Vaccine 2009; 28: 484-493.
100. Skinner GR, Woodman C, Hartley C, et al. Early experience with "antigenoid" vaccine Ac NFU1(S-) MRC towards prevention or modification of herpes genitalis. Developments in Biological Standardization 1982; 52: 333-344.
101. Skinner GR, Woodman CB, Hartley CE, et al. Preparation and immunogenicity of vaccine Ac NFU1 (S-) MRC towards the prevention of herpes genitalis. The British Journal of Venereal Diseases 1982; 58: 381-386.
102. Skinner GRB, Fink CG, Cowan M, et al. Follow-up report on 50 subjects vaccinated against herpes genitalis with Skinner vaccine. Medical Microbiology and Immunology 1987; 176: 161-168.
103. Skinner GR, Turyk ME, Benson CA, et al. The efficacy and safety of Skinner herpes simplex vaccine towards modulation of herpes genitalis; report of a prospective double-blind placebo-controlled trial. Medical Microbiology and Immunology 1997; 186: 31-36.
104. De Maria A, Tundo P, Romano A, Grima P. Anti-HSV-1 herpes vaccination by LUPIDON H: preliminary results. Advances in Experimental Medicine and Biology 1995; 371: 1599-1600.
105. Schmersahl P, Rüdiger G. Results of treatment with the herpes simplex antigen Lupidon H, resp. Lupidon G. Zeitschrift für Hautkrankheiten 1975; 50: 105-112.
106. Stanberry LR, Cunningham AL, Mindel A, et al. Prospects for control of herpes simplex virus disease through immunization. Clinical Infectious Diseases 2000; 30: 549-566. DOI: 10.1086/313687
107. Meignier B, Jourdier TM, Norrild B, Pereira L, Roizman B. Immunization of experimental animals with reconstituted glycoprotein mixtures of herpes simplex virus 1 and 2: protection against challenge with virulent virus. Journal of Infectious Diseases 1987; 155: 921-930.
108. Bourne N, Bravo FJ, Francotte M, et al. Herpes simplex virus (HSV) type 2 glycoprotein D subunit vaccines and protection against genital HSV-1 or HSV-2 disease in guinea pigs. The Journal of Infectious Diseases 2003; 187: 542-549.
109. Lasky LA, Dowbenko DJ. DNA sequence analysis of the type-common glycoprotein-D genes of herpes simplex virus types 1 and 2. DNA 1984; 3: 23-29.
110. Byars NE, Fraser-Smith EB, Pecyk RA, et al. Vaccinating guinea pigs with recombinant glycoprotein D of herpes simplex virus in an efficacious adjuvant formulation elicits protection against vaginal infection. Vaccine 1994; 12: 200-209.
111. O'Hagan D, Goldbeck C, Ugozzoli M, Ott G, Burke RL. Intranasal immunization with recombinant gD2 reduces disease severity and mortality following genital challenge with herpes simplex virus type 2 in guinea pigs. Vaccine 1999; 17: 2229-2236.
112. Straus SE, Wald A, Kost RG, et al. Immunotherapy of recurrent genital herpes with recombinant herpes simplex virus type 2 glycoproteins D and B: results of a placebo-controlled vaccine trial. Journal of Infectious Diseases 1997; 176: 1129-1134.
113. Burke RL. Current developments in herpes simplex virus vaccines. Seminars in Virology 1993; 4: 187-197.
114. Straus SE, Corey L. Placebo-controlled trial of vaccination with recombinant glycoprotein D of herpes simplex virus. Lancet 1994; 343: 1460.
115. Langenberg AGM, Burke RL, Adair SF, et al. A recombinant glycoprotein vaccine for herpes simplex type 2: safety and efficacy. Annals of Internal Medicine 1995; 122: 889-898. DOI: 10.1059/0003-4819-122-12-199506150-00001
116. Kohl S, Charlebois Edwin D, Sigouroudinia M, et al. Limited antibody-dependent cellular cytotoxicity antibody response induced by a herpes simplex virus type 2 subunit vaccine. The Journal of Infectious Diseases 2000; 181: 335-339. DOI: 10.1086/315208
117. Bernstein DI, Aoki FY, Tyring SK, et al. Safety and immunogenicity of glycoprotein D-adjuvant genital herpes vaccine. Clinical Infectious Diseases 2005; 40: 1271-1281. DOI: 10.1086/429240
118. Stanberry LR, Spruance SL, Cunningham AL, et al. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. The New England Journal of Medicine 2002; 347: 1652-1661. DOI: 10.1056/NEJMoa011915
119. Belshe RB, Leone PA, Bernstein DI, et al. Efficacy results of a trial of a herpes simplex vaccine. The New England Journal of Medicine 2012; 366: 34-43. DOI: 10.1056/NEJMoa1103151
120. Kato H, Shibano M, Saito T, et al. Relationship between hemolytic activity and adsorption capacity of aluminum hydroxide and calcium phosphate as immunological adjuvants for biologicals. Microbiology and Immunology 1994; 38: 543-548.
121. He Q, Mitchell A, Morcol T, Bell SJD. Calcium phosphate nanoparticles induce mucosal immunity and protection against herpes simplex virus type 2. Clinical and Diagnostic Laboratory Immunology 2002; 9: 1021-1024. DOI: 10.1128/cdli.9.5.1021-1024.2002
122. Zhang X, Chentoufi AA, Dasgupta G, et al. A genital tract peptide epitope vaccine targeting TLR-2 efficiently induces local and systemic CD8+ T cells and protects against herpes simplex virus type 2 challenge. Mucosal Immunology 2009; 2: 129-143.
123. Tirabassi RS, Ace CI, Levchenko T, et al. A mucosal vaccination approach for herpes simplex virus type 2. Vaccine 2011; 29: 1090-1098.
124. Bettahi I, Nesburn AB, Yoon S, et al. Protective immunity against ocular herpes infection and disease induced by highly immunogenic self-adjuvanting glycoprotein D lipopeptide vaccines. Investigative Ophthalmology & Visual Science 2007; 48: 4643-4653. DOI: 10.1167/iovs.07-0356
125. BenMohamed L, Wechsler SL, Nesburn AB. Lipopeptide vaccines-yesterday, today, and tomorrow. The Lancet Infectious Diseases 2002; 2: 425-431.
126. Halford WP, Püschel R, Gershburg E, Wilber A, Gershburg S, Rakowski B. A live-attenuated HSV-2 ICP0- virus elicits 10 to 100 times greater protection against genital herpes than a glycoprotein D subunit vaccine. PLoS One 2011; 6: e17748.
127. Roldão A, Mellado MCM, Castilho LR, Carrondo MJT, Alves PM. Virus-like particles in vaccine development. Expert Review of Vaccines 2010; 9: 1149-1176.
128. Thomson SA, Jaramillo AB, Shoobridge M, et al. Development of a synthetic consensus sequence scrambled antigen HIV-1 vaccine designed for global use. Vaccine 2005; 23: 4647-4657.
129. Altin JG, Parish CR. Liposomal vaccines-targeting the delivery of antigen. Methods 2006; 40: 39-52. DOI: 10.1016/j.ymeth.2006.05.027
130. Goulleret Nicolas N, Mauvisseau E, Essevaz-Roulet M, Quinlivan M, Breuer J. Safety profile of live varicella virus vaccine (Oka/Merck): five-year results of the European varicella zoster virus identification program (EU VZVIP). Vaccine 2010; 28: 5878-5882.
131. Strasser JE, Arnold RL, Pachuk C, Higgins TJ, Bernstein DI. Herpes simplex virus DNA vaccine efficacy: effect of glycoprotein D plasmid constructs. The Journal of Infectious Diseases 2000; 182: 1304-1310. DOI: 10.1086/315878
132. Koelle DM, Magaret A, McClurkan CL, et al. Phase I dose-escalation study of a monovalent heat shock protein 70-herpes simplex virus type 2 (HSV-2) peptide-based vaccine designed to prime or boost CD8 T-cell responses in HSV-naive and HSV-2-infected subjects. Clinical and Vaccine Immunology 2008; 15: 773-782. DOI: 10.1128/cvi.00020-08
133. + cellular immunity and protective efficacy. Vaccine 2011; 29: 8530-8542.
134. Knipe DM. Replication-defective herpes simplex virus mutant strains as genital herpes vaccines and vaccine vectors. In Replicating Vaccines. Birkhäuser Advances in Infectious Diseases, Dormitzer PR, Mandl CW, Rappuoli R (eds). Springer: Basel, 2011; 285-298.
135. Casanova G, Cancela R, Alonzo L, et al. A double-blind study of the efficacy and safety of the ICP10deltaPK vaccine against recurrent genital HSV-2 infections. Cutis 2002; 70: 235-239.
136. Roberts JSC, Uttridge JA, Hickling JK, Al E. Safety tolerability and viral containment of a disabled infectious single cycle HSV-2 vaccine evaluated in phase 1 clinical trials in HSV-2 seropositive and seronegative volunteers. In 8th International Congress on Infectious Diseases, Boston, MA, 1998.
137. Cappel R, de Cuyper F, Rickaert F. Efficacy of a nucleic acid free herpetic subunit vaccine. Archives of Virology 1980; 65: 15-23.
138. Kutinová L, Benda R, Kalos Z, et al. Placebo-controlled study with subunit herpes simplex virus vaccine in subjects suffering from frequent herpetic recurrences. Vaccine 1988; 6: 223-228.
139. Barkhaleva OA, Ladyzhenskaia IP, Vorobeva MS, et al. Vitaherpavac is the first Russian herpes simplex virus vaccine obtained on the Vero B continuous cell line [article in Russian]. Voprosy Virusologii 2009; 54: 33-37.
140. Hosken N, McGowan P, Meier A, et al. Diversity of the CD8 T cell response to herpes simplex virus type 2 proteins among persons with genital herpes. Journal of Virology 2006; 80: 5509-5515.
141. Goel N, Rong Q, Zimmerman D, Rosenthal KS. A L.E.A.P.S.(TM) heteroconjugate vaccine containing a T cell epitope from HSV-1 glycoprotein D elicits Th1 responses and protection. Vaccine 2003; 21: 4410-4420.